Evidence map›Paper›PMID 35921177›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

A Druggable Rheostat for Ewing Sarcoma?

Kurt R Weiss, Kelly M Bailey

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kurt R WeissDepartment of Orthopedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0003-3859-728X
Kelly M BaileyDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0003-3925-3243
University of Pittsburgh · US

Funding

Molecular Basis of Pediatric DiseaseK12HD052892 · NICHD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TERENCE S. DERMODY · 2007 to 2026
$6.5M
DNA Damage and Immunogenicity in Ewing SarcomaK08CA252178 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BAILEY, KELLY · 2021 to 2025
$765k
NCI NIH HHS K08 CA252178NICHD NIH HHS K12 HD052892
6 · The paper itself

Abstract

The posterior HOXD enhancer is an EWSR1::FLI1-dependent regulator of HOXD13 expression in Ewing sarcoma. HOXD13 expression promotes a mesenchymal cell state. Through antagonistic transcriptional programs, EWSR1::FLI1 and HOXD13 serve as master regulators of Ewing cell plasticity. Targeting Ewing cells as they exist in/transition between mesenchymal states is a priority. See related article by Apfelbaum et al., p. 4466.

Indexed as

Sarcoma, EwingCell Line, TumorGene Expression Regulation, NeoplasticHumansOncogene Proteins, FusionProto-Oncogene Protein c-fli-1RNA-Binding Protein EWSTranscription FactorsOncogene Proteins, FusionProto-Oncogene Protein c-fli-1RNA-Binding Protein EWSTranscription Factors

Identifiers

PMID35921177
PMCPMC9588653
OpenAlexW4289638073

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.